Trump signs law that subjects all biosimilar patent settlements to FTC scrutiny
Heightened concern over pay-for-delay strategies has driven the legislation at a time when the number of biosimilars being approved is set to rise sharply
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.